Maeda Ryo, Suda Takashi, Hachimaru Ayumi, Tochii Daisuke, Tochii Sachiko, Takagi Yasushi
Division of Thoracic and Cardiovascular Surgery, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
J Thorac Dis. 2017 Jan;9(1):176-186. doi: 10.21037/jtd.2017.01.30.
The objective of this study was to assess the preoperative serum carcinoembryonic antigen (CEA) level in patients with clinical stage IA non-small cell lung cancer (NSCLC) and to evaluate its clinical significance.
Between January 2005 and December 2014, a total of 378 patients with clinical stage IA NSCLC underwent complete resection with systematic node dissection. The survival rate was estimated starting from the date of surgery to the date of either death or the last follow-up by the Kaplan-Meier method. Univariate analyses by log-rank tests were used to determine prognostic factors. Cox proportional hazards ratios were used to identify independent predictors of poor prognosis. Clinicopathological predictors of lymph node metastases were evaluated by logistic regression analyses.
The 5-year survival rate of patients with an elevated preoperative serum CEA level was significantly lower than that of patients with a normal CEA level (75.5% 87.7%; P=0.02). However, multivariate analysis did not show the preoperative serum CEA level to be an independent predictor of poor prognosis. Postoperative pathological factors, including lymphatic permeation, visceral pleural invasion, and lymph node metastases, tended to be positive in patients with an elevated preoperative serum CEA level. In addition, the CEA level was a statistically significant independent clinical predictor of lymph node metastases.
The preoperative serum CEA level was not an independent predictor of poor prognosis in patients with pathological stage IA NSCLC but was an important clinical predictor of tumor invasiveness and lymph node metastases in patients with clinical stage IA NSCLC. Therefore, measurement of the preoperative serum CEA level should be considered even for patients with early-stage NSCLC.
本研究的目的是评估临床ⅠA期非小细胞肺癌(NSCLC)患者术前血清癌胚抗原(CEA)水平,并评估其临床意义。
2005年1月至2014年12月期间,共有378例临床ⅠA期NSCLC患者接受了完整切除及系统性淋巴结清扫。从手术日期至死亡或最后随访日期,采用Kaplan-Meier法估计生存率。通过对数秩检验进行单因素分析以确定预后因素。采用Cox比例风险比来识别预后不良的独立预测因素。通过逻辑回归分析评估淋巴结转移的临床病理预测因素。
术前血清CEA水平升高的患者5年生存率显著低于CEA水平正常的患者(75.5%对87.7%;P = 0.02)。然而,多因素分析未显示术前血清CEA水平是预后不良的独立预测因素。术前血清CEA水平升高的患者术后病理因素,包括淋巴管浸润、脏层胸膜侵犯和淋巴结转移,往往呈阳性。此外,CEA水平是淋巴结转移的具有统计学意义的独立临床预测因素。
术前血清CEA水平不是病理ⅠA期NSCLC患者预后不良的独立预测因素,但却是临床ⅠA期NSCLC患者肿瘤侵袭性和淋巴结转移的重要临床预测因素。因此,即使是早期NSCLC患者也应考虑检测术前血清CEA水平。